The Pharmacovigilance Risk Assessment Committee of the European Medicines Agency (PRAC) recommends new measures to avoid dosing errors with medicinal products containing methotrexate

13.09.2019 Updated 22.10.2019 2580 views

Комітет з оцінки ризиків у фармаконагляді Європейської медичної агенції (PRAC) рекомендує нові заходи для уникнення помилок при дозуванні лікарських засобів, що містять у своєму складі methotrexateDOC · 41 КБ

Завантажити

The Pharmacovigilance Risk Assessment Committee of the European Medicines Agency (PRAC) recommends new measures to avoid dosing errors with medicinal products containing methotrexate

Forum "PHARMEXPERT 2026: pharmaceutical market in the new regulatory reality"

Forum "Clinical and preclinical studies in wartime: organization and development prospects"

Pharmaceutical forum "PHARMEXPERT 2025. eCTD and pricing in Ukraine – a strategic path to integration into the international regulatory space"

PHARMEXPERT 2024. Standards. Innovations. European integration

The Pharmacovigilance Risk Assessment Committee of the European Medicines Agency (PRAC) recommends new measures to avoid dosing errors with medicinal products containing methotrexate

Other materials in this section

Forum "PHARMEXPERT 2026: pharmaceutical market in the new regulatory reality"

Forum "Clinical and preclinical studies in wartime: organization and development prospects"

Pharmaceutical forum "PHARMEXPERT 2025. eCTD and pricing in Ukraine – a strategic path to integration into the international regulatory space"

PHARMEXPERT 2024. Standards. Innovations. European integration